UB Paderborn / Katalog / Suche / in CDI

Es ist ein Fehler in der Kommunikation mit einem externen System aufgetreten. Bitte versuchen Sie Ihre letzte Aktion erneut. Sollte der Fehler bestehen bleiben, setzen Sie sich bitte mit dem Informationszentrum der Bibliothek in Verbindung oder versuchen Sie es später erneut.

1 – 25 von 74

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

British journal of dermatology (1951), 2013-04, Vol.168 (4), p.844-854

2013

Volltextzugriff (PDF)

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

British journal of dermatology (1951), 2012-04, Vol.166 (4), p.861-872

2012

Volltextzugriff (PDF)

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up

British journal of dermatology (1951), 2015-05, Vol.172 (5), p.1371-1383

2015

Volltextzugriff (PDF)

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

Journal of the European Academy of Dermatology and Venereology, 2013-12, Vol.27 (12), p.1535-1545

2013

Volltextzugriff (PDF)

The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection

British journal of dermatology (1951), 2012-11, Vol.167 (5), p.1145-1152

2012

Volltextzugriff (PDF)

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies

British journal of dermatology (1951), 2011-04, Vol.164 (4), p.862-872

2011

Volltextzugriff (PDF)

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2019-09, Vol.381 (13), p.1201-1214

2019

Volltextzugriff (PDF)

Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials

Journal of the European Academy of Dermatology and Venereology, 2011-07, Vol.25 (7), p.851-857

2011

Volltextzugriff (PDF)

Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome

Arteriosclerosis, thrombosis, and vascular biology, 2006-01, Vol.26 (1), p.182-188

2006

Volltextzugriff (PDF)

SAT0287 Long-Term Safety Of Ustekinumab: 5 Years of Follow-Up from the Psoriasis Clinical Development Program Including Patients with Psoriatic Arthritis

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A680-A680

2013

Volltextzugriff (PDF)

PCN107 Economic Burden of Complications Associated with Transthoracic Needle Biopsy of Pulmonary Nodules: A Retrospective Cohort Analysis

Value in health, 2021-06, Vol.24, p.S39-S39

2021

Volltextzugriff (PDF)

Pharmacological management of high triglycerides and low high-density lipoproetin cholesterol

Current Opinion in Pharmacology, 2001-04, Vol.1 (2), p.113-120

2001

Volltextzugriff (PDF)

Physicians recommendations for and personal use of low-fat and low-carbohydrate diets

International Journal of Obesity, 2005-02, Vol.29 (2), p.251-253

2005

Volltextzugriff (PDF)

OC-045 Efficacy & safety of dose adjustment & delayed response to ustekinumab in moderate–severe crohn’s disease patients: results from im-uniti maintenance study

Gut, 2017-07, Vol.66 (Suppl 2), p.A23

2017

Volltextzugriff (PDF)

P477 Clinical remission by legacy vs. FDA definitions: definition justification and results from UNIFI Study

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S350-S351

2019

Volltextzugriff (PDF)

A Randomized Trial of a Low-Carbohydrate Diet for Obesity

The New England journal of medicine, 2003-05, Vol.348 (21), p.2082-2090

2003

Volltextzugriff (PDF)

P681 Ustekinumab therapy induced clinically meaningful improvement and remission as measured by the Inflammatory Bowel Disease Questionnaire: Results from the phase 3 UNIFI induction and maintenance studies

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S460-S460

2019

Volltextzugriff (PDF)

P406 General health status in patients with moderate to severe ulcerative colitis receiving ustekinumab: results from the Phase 3 UNIFI induction and maintenance studies

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S311-S312

2019

Volltextzugriff (PDF)

P312 Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFI

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S256-S257

2019

Volltextzugriff (PDF)

DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S061-S062

2019

Volltextzugriff (PDF)

P311 Pharmacokinetics and exposure–response relationships of intravenously administered ustekinumab during induction treatment in patients with ulcerative colitis: Results from the UNIFI induction study

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S255-S256

2019

Volltextzugriff (PDF)

DOP47 Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S054-S055

2019

Volltextzugriff (PDF)

OP37 Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFI

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S025-S026

2019

Volltextzugriff (PDF)

Guggul for hyperlipidemia: A review by the Natural Standard Research Collaboration

Complementary therapies in medicine, 2005-12, Vol.13 (4), p.279-290

2005

Volltextzugriff (PDF)

Infections survenues au cours du programme d’études cliniques sur le traitement du psoriasis par l’ustekinumab : rapport final portant sur un suivi de cinq ans

Annales de dermatologie et de vénéréologie, 2013-12, Vol.140 (12), p.S553-S553

2013

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(64)

Publikationsform

Artikel
(73)
Reviews
(1)

Sprache

Englisch
(69)
Französisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials

Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome

SAT0287 Long-Term Safety Of Ustekinumab: 5 Years of Follow-Up from the Psoriasis Clinical Development Program Including Patients with Psoriatic Arthritis

PCN107 Economic Burden of Complications Associated with Transthoracic Needle Biopsy of Pulmonary Nodules: A Retrospective Cohort Analysis

Pharmacological management of high triglycerides and low high-density lipoproetin cholesterol

Physicians recommendations for and personal use of low-fat and low-carbohydrate diets

OC-045 Efficacy & safety of dose adjustment & delayed response to ustekinumab in moderate–severe crohn’s disease patients: results from im-uniti maintenance study

P477 Clinical remission by legacy vs. FDA definitions: definition justification and results from UNIFI Study

A Randomized Trial of a Low-Carbohydrate Diet for Obesity

P681 Ustekinumab therapy induced clinically meaningful improvement and remission as measured by the Inflammatory Bowel Disease Questionnaire: Results from the phase 3 UNIFI induction and maintenance studies

P406 General health status in patients with moderate to severe ulcerative colitis receiving ustekinumab: results from the Phase 3 UNIFI induction and maintenance studies

P312 Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFI

DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial

P311 Pharmacokinetics and exposure–response relationships of intravenously administered ustekinumab during induction treatment in patients with ulcerative colitis: Results from the UNIFI induction study

DOP47 Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study

OP37 Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFI

Guggul for hyperlipidemia: A review by the Natural Standard Research Collaboration

Infections survenues au cours du programme d’études cliniques sur le traitement du psoriasis par l’ustekinumab : rapport final portant sur un suivi de cinq ans

Suchergebnisse filtern